MONMOUTH JUNCTION, N.J., Sept. 16, 2019 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its

LANDING, New Jersey, Sept. 16, 2019 /PRNewswire/ -- MoriKol™, a naturally derived, marine-based tripeptide collagen ingredient from kosher, warm-water fish makes its debut in the US. The ingredient is a clean-label, consumer friendly alternative to bovine and porcine collagen. Through a pioneering licensing deal, Dolcas makes this uniqu

SAN JOSE, Calif., Sept. 16, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body's immune system to fight cancer, congrat

MENLO PARK, Calif., Sept. 16, 2019 /PRNewswire/ -- Gala Therapeutics, Inc. (Gala), a developer of medical devices to treat pulmonary disease, announced the U.S. Food and Drug Administration (FDA) granted Breakthrough Device Designation (FDA) for the RheOxTM Bronchial RheoplastyTM system. RheOx uses a minimally invasive procedure to deliver

JERUSALEM, Sept. 16, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces that two posters in support of the Company's Phase 3 clinical development program for the Accordion Pill™ Carbidopa/Levodopa (AP-CD/LD), will be presented at the upcoming International Congress of Parkinson's and Movement Disorder S

WARSAW, Ind., Sept. 16, 2019 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, has announced 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the JuggerStitch™ meniscal repair device. The JuggerStitch device is the next generation of this pioneering meniscus repair tech

NEW YORK, Sept. 16, 2019 /PRNewswire/ -- The respected peer-reviewed, medical journal The Lancet will publish today the results of a study presented in May at the National Kidney Foundation's 2019 Spring Clinical Meetings as a late breaking clinical trial that may offer hope to some patients with advanced chronic kidney disease (CKD) whose hypertension is dif

HOUSTON, Sept. 16, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced its sponsored research at MD Anderson Cancer Center has resulted in the filing of a new patent on behalf of MD Anderson Can

ROCKVILLE, Md., Sept. 16, 2019 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing therapeutics and pharmaceutical products, announces that the Chinese National Medical Product Administration (NMPA), the Chinese FDA, has accepted the clinical trial application for CNCT19 (

HighlightsAdAlta secures commercial agreement for its i-body platform with global medical technology and diagnostics firm, GE Healthcare. Under the licensing deal, the two companies will develop i-bodies for diagnostic imaging. AdAlta will screen its novel i-body library on a number of targets in order to identify i-bodies that GE can use as imaging agents, starting with Granzyme B.